Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    Bocaliner
Previous Study | Return to List | Next Study

Study of a New Medical Device for Oral Mucositis (MDOM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05104268
Recruitment Status : Not yet recruiting
First Posted : November 2, 2021
Last Update Posted : November 23, 2021
Sponsor:
Collaborator:
Hematology Center after Prof. R. Yeolyan
Information provided by (Responsible Party):
E2Bio Life Sciences, LLC

Brief Summary:
This is a single-center randomized controlled trial of a new medical device (Bocaliner™) that has been designed to improve the treatment of chemotherapy-induced oral mucositis in patients undergoing cancer treatment. The goal of this study is to determine tolerance and response to the use of Bocaliner™ as reported by patients with chemotherapy and/or radiation therapy-induced oral mucositis.

Condition or disease Intervention/treatment Phase
Oral Mucositis Stem Cell Transplant Complications Device: Bocaliner Phase 1 Phase 2

Detailed Description:

All patients will be referred by their treating physicians to the designated study healthcare providers. Patients will have been diagnosed with oral mucositis and will be receiving oral topical medication for oral pain as well as other problems related to oral mucositis. All subjects will sign an informed consent form.

Initially, subjects will undergo an oral examination and for determination of the World Health Organization (WHO) Oral Toxicity Scale and will then complete a General Oral Mucositis Assessment Scale.

Subjects will then be randomized into two groups. Group 1 will continue standard therapy with oral topical agents for oral mucositis. Group 2 will additionally receive Bocaliner™ devices along with cleaning materials with instructions about device use and cleaning. Subjects in the Group 2 will use Bocaliner™ with each topical treatment for oral mucositis up to 5 times per day for 2 weeks or shorter if not tolerated.

Subjects assigned to the Group 1 will continue the original therapy for oral mucositis, including oral topical treatments and general hygiene measures. Participants that are randomized to the Group 2 will place Bocaliner™ inside of their mouth for 5 minutes and fill out the Initial Bocaliner™ Questionnaire. They will then continue all original therapy for oral mucositis, including oral topical treatments and general hygiene, and will place the Bocaliner™ device inside of their mouth and hold it in place up to 40 minutes as instructed after each topical treatment.

All subjects will be contacted by the Research Coordinator via phone call at 5 and 10 days after the initial enrollment and invited to answer the questions from the Modified PROMS Questionnaire at the hospital. Alternatively, the questionnaire can be provided via email, or the questions can be answered via phone call, if preferred by a patient. Subjects in Group 2 will describe their experience of using Bocaliner™ through the Bocaliner™ Follow-up Questionnaire. All subjects will give a detailed description of their current medication usage for oral mucositis. Participants from both groups will return to their practitioners after 14 days and undergo a general oral examination. The WHO Oral Toxicity Scale will be used to assess the grade of oral mucositis. Subjects will also complete the Modified PROMS Questionnaire at days 5, 10, and 14 to understand the impact of standard treatment vs Bocaliner™ on symptoms related to oral mucositis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will then be randomized into two groups. Group 1 will continue standard therapy with oral topical agents for oral mucositis. Group 2 will additionally receive Bocaliner™ devices along with cleaning materials with instructions about device use and cleaning. Subjects in the Group 2 will use Bocaliner™ with each topical treatment for oral mucositis up to 5 times per day for 2 weeks or shorter if not tolerated.
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)
Estimated Study Start Date : November 30, 2021
Estimated Primary Completion Date : May 15, 2022
Estimated Study Completion Date : December 31, 2022

Arm Intervention/treatment
Active Comparator: Standard Therapy
Subjects will then be randomized into two groups. The Standard Therapy Group will continue their usual therapy with oral topical agents for oral mucositis.
Device: Bocaliner
Bocaliner is an orally inserted device that is held within the mouth following the administration of mouthwashes, gels, and rinses that are used to treat pain associated with oral mucositis, and to reduce inflammation and to accelerate healing of oral mucositis.
Other Name: Standard Treatments for Oral Mucositis

Experimental: Bocaliner
Participants that are randomized to the Bocaliner Group will place Bocaliner™ inside of their mouth for 5 minutes and fill out the Initial Bocaliner™ Questionnaire. They will then continue all original therapy for oral mucositis, including oral topical treatments and general hygiene, and will place the Bocaliner™ device inside of their mouth and hold it in place up to 40 minutes as instructed after each topical treatment.
Device: Bocaliner
Bocaliner is an orally inserted device that is held within the mouth following the administration of mouthwashes, gels, and rinses that are used to treat pain associated with oral mucositis, and to reduce inflammation and to accelerate healing of oral mucositis.
Other Name: Standard Treatments for Oral Mucositis




Primary Outcome Measures :
  1. Change in Patient-Reported Oral Mucositis Symptom (The Modified PROMS Questionnaire) Pain Score [ Time Frame: 5, 10, and 14 days ]

    The modified PROMS score is designed to measure symptoms and quality of life in patients with oral mucositis. It consists of twelve questions. The range in scores for each section is 0 to 100. Higher scores on the Modified PROMS indicate worse outcomes.

    The range in the Pain Score of the Modified PROMS Questionnaire is from 0 to 100.



Secondary Outcome Measures :
  1. Change in other symptoms of oral mucositis on the Patient-Reported Oral Mucositis Symptom (The Modified PROMS Questionnaire. [ Time Frame: 5, 10, and 14 days ]
    The modified PROMS score is designed to measure symptoms and quality of life in patients with oral mucositis. It consists of twelve questions. The range in scores for each question is 0 to 100. Higher scores on the PROMS Questionnaire indicate worse outcomes.

  2. Change of oral mucositis grade in the World Health Organization Grade,(WHO Mucositis Grade) [ Time Frame: 5, 10, and 14 days ]
    The WHO Mucositis grade is based on the appearance of the oral mucosa and the effect of oral mucositis on nutritional intake. The range of grades is from 1 to 4. Higher WHO Mucositis grades indicate worse outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Symptomatic chemotherapy-induced oral mucositis
  • Need for oral topical therapy for symptomatic treatment
  • Absence of other chronic oral disorders
  • Properly obtained written informed consent
  • Age of 18 years or older
  • Patient is willing to use the Bocaliner™ device for 2 weeks
  • No concurrent use of medications modulating pain

Exclusion Criteria:

  • Chronic oral conditions other than chemotherapy-induced oral mucositis
  • No informed consent
  • Age of <18
  • Inability to place the device in his/her mouth and keep it in place for at least 10 minutes due to severe oral pain, large lesions, or any other reason
  • Inability/unwillingness to wear Bocaliner™ for the study period
  • Concurrent use of pain-modulating agents
  • Individuals with known allergies to silicone materials
  • Individuals with severe difficulties to communicate and understand

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05104268


Contacts
Layout table for location contacts
Contact: Eli D Ehrenpreis, MD 8479771318 e2bioconsults@gmail.com
Contact: Artem T Oganesyan, MD +374 10 283800 a.t.oganesyan@gmail.com

Locations
Layout table for location information
Armenia
Hematology Center after Prof. R. Yeolyan MH RA
Yerevan, Armenia, 0014
Contact: Yervand Hakobyan, MD    TBA    armhema@gmail.com   
Contact: Artem Oganesyan, MD    TBA    A.T.oganseyan@gmail.com   
Sponsors and Collaborators
E2Bio Life Sciences, LLC
Hematology Center after Prof. R. Yeolyan
Investigators
Layout table for investigator information
Principal Investigator: Yervand Hakoban, MD PhD Hematology Center after Prof. R. Yeolyan, MH RA
Publications of Results:

Layout table for additonal information
Responsible Party: E2Bio Life Sciences, LLC
ClinicalTrials.gov Identifier: NCT05104268    
Other Study ID Numbers: BL001
First Posted: November 2, 2021    Key Record Dates
Last Update Posted: November 23, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Deidentified data will be available to other research scientists who meet screening criteria by principal investigator.
Supporting Materials: Clinical Study Report (CSR)
Time Frame: January 2023 through January 2024
Access Criteria:
  1. Data scientists from accredited clinical organizations
  2. Accepted review by principal investigator for the planned purpose for data use

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by E2Bio Life Sciences, LLC:
Stem Cell Transplantation
Oral Mucositis
Cancer
Complications of chemotherapy
Oral Inflammation
Oral Pain
Pharmacokinetics
Oral Topical Therapy
Oral Inserted Device
Oral Resonance Time
Additional relevant MeSH terms:
Layout table for MeSH terms
Mucositis
Stomatitis
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases